Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Kaposi Sarcoma Market by Type, by Treatment, by End-Users, and By Region" report has been added to ResearchAndMarkets.com's offering.
The Global Kaposi Sarcoma Market, valued at USD 149.2 million in 2023, is projected to reach USD 247.6 million by 2034, showcasing a CAGR of 4.7%. This extensive study provides key insights into the market segmentation, including type, treatment, end-user, and region, with detailed revenue forecasts during the forecast period. The market is primarily driven by the increasing prevalence of HIV/AIDS, which raises the incidence rate of Kaposi sarcoma among individuals with weakened immune systems.
The report delineates various segments of the market, with the epidemic (AIDS-associated) Kaposi sarcoma segment accounting for a substantial revenue share due to heightened research and development activities and strategic collaborations in the pharmaceutical landscape.
In terms of treatment, the highly active antiretroviral therapy (HAART) segment has emerged as a dominant force in the market. Ongoing advancements in HAART have been instrumental in controlling HIV replication, strengthening the immune response, and consequently reducing the incidence of AIDS-associated Kaposi sarcoma.
The hospital segment stands out among end-users due to its pivotal role in providing comprehensive care for Kaposi sarcoma patients, including diagnosis, treatment, and long-term management.
Geographic Market Analysis
The report covers an extensive geographic analysis, identifying the North American region as the largest market in terms of revenue share, attributed to its advanced healthcare infrastructure and robust R&D activities. Conversely, the Asia Pacific region is anticipated to register the highest CAGR, owing to improving healthcare services, an increase in the patient pool, and growing medical expenditure in the area.
Competitive Landscape and Key Market Players
The competitive landscape is thoroughly analyzed, featuring major players who are influencing market dynamics through innovative product development, strategic partnerships, and engaging in extensive clinical trials to fortify their market positions.
Companies Mentioned
- Bristol-Myers Squibb
- Merck & Co. Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- Novartis International AG
- Celgene Corporation (Acquired by Bristol-Myers Squibb)
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- AstraZeneca plc
- Bayer AG
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023-2034 |
| Estimated Market Value (USD) in 2023 | $149.2 Million |
| Forecasted Market Value (USD) by 2034 | $247.6 Million |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/ev7d4y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
